Although up-regulation of apoE secretion via the ABCA1 pathway is an attractive target for AD and other age-related neurological disorders, the clinical application of modulators of this pathway has not yet been established, partly because of their side effects [12,13]. This evidence concerns the gene ABCA1 and Alzheimer disease.